IMPORTANT INFORMATION FOR PRIVATE INVESTORS

Our investments place your capital at risk. We do not provide investment, tax or legal advice and we recommend you seek professional advice if you are considering investing with us. You may lose part or all of the amount you invest with us. We invest in unquoted shares in small companies. The value of these shares can be volatile, and the shares are often difficult to sell. The tax reliefs associated with our investments depend on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results. Our forecasts and performance targets cannot accurately predict how investments will perform.

ACCEPT DECLINE
Change Visitor Type Sign up to our newsletter

NEWS & VIEWS

Oxford Capital and our portfolio companies

Portfolio Company – Curve announces Lithuanian subsidiary

By Oxford Capital | October 26, 2020
Curve announces a Lithuanian subsidiary to further accelerate its growth in Europe.
Read More

Portfolio Company – Push Doctor raises £14m in new fundraising round

By Oxford Capital | October 26, 2020
Push Doctor has announced it has completed its latest funding round, to help scale up its services following a boost to customer numbers through the pandemic.
Read More

Push Doctor case study – the value of EIS investing in driving growth

By Oxford Capital | October 26, 2020
Case study of our portfolio company, Push Doctor from EISA – highlighting the benefit of EIS investing in driving growth for early stage companies.
Read More

Christmas Carol film set to open in November 2020 – Media EIS portfolio

By Oxford Capital | October 19, 2020
A new adaptation of Charles Dickens’ “A Christmas Carol,” with an all-star voice cast including Carey Mulligan, Martin Freeman, Daniel Kaluuya, Simon Russell Beale and Andy Serkis, is set for a Nov. 20 U.K. release across both cinemas and theaters.  This is a fantastic film, selected by our media EIS partner.
Read More

Oxford BioTherapeutics expands its partnership with Boehringer Ingelheim

By Oxford Capital | October 14, 2020
Portfolio company, Oxford BioTherapeutics has expanded its partnership with Boehringer Ingelheim to do more to target difficult-to-reach cancers and deliver best in class treatment for cancer patients.
Read More

Portfolio company – Hometree secures £7m in latest fundraising round

By Oxford Capital | October 13, 2020
Insurtech Hometree raises £7m following a surge in demand and new partnerships through COVID-19.  The funding round led by global investment firm Anthemis, and existing investors DN Capital and Literacy Capital. Other participants included Gumtree Founder Michael Pennington, Oxford Capital, Jon Moulton and many of Hometree’s existing shareholders.
Read More

Oxford Capital recognised at BVCA Excellence in ESG 2020 awards

By Oxford Capital | October 13, 2020
BVCA recognises Excellence in ESG 8 October 2020  The importance of ESG and responsible investment has never been more urgent for the private equity and venture capital industry. The COVID-19 pandemic has reinforced the need to place climate change, health and safety, and other important environmental, social and governmental issues at the heart of the…
Read More

Curve and Moneybox both featured in Business Cloud’s 100 FinTech Disruptors list

By Oxford Capital | September 29, 2020
Our portfolio companies, Curve and Moneybox both in feature in the Business Cloud 100 Fintech Disruptors list for 2020 – which highlights UK companies transforming banking, personal finance, payments, insurance, investments, charitable donations, accountancy and compliance.
Read More

Podcast interview with Romanie Thomas – Founder of Juggle Jobs

By Oxford Capital | September 28, 2020
Interesting interview with Juggle Jobs (our portfolio company) Founder, Romanie Thomas on the impact of the pandemic on flexible working and the future of work.
Read More

LinkedIn Top Startups 2020 – Moneybox named one of the top 10 UK companies to watch

By Oxford Capital | September 23, 2020
Our portfolio company, Moneybox is named as one of the UK’s top 10 start ups for 2020, by LinkedIn.  It has been rated for major milestones in 2020, including its £30m fundraising round and £7m crowdfunding campaign.  In addition, it hit £1bn in assets under administration in July.    
Read More

Awards

  • BEST EIS
    FUND MANAGER    2013,2012,2010 AND 2006

  • VENTURE CAPITAL
    HOUSE OF THE YEAR    WINNER 2013 AND 2005

  • INVESTOR OF
    THE YEAR    WINNER IN 2012 AND 2013

  • MOST IMPACTFUL
    INVESTMENT    WINNER 2017

  • BEST ANGEL
    SYNDICATE    WINNER 2018

  • BVCA Excellence in ESG
    GP CATEGORY    COMMENDED 2020